10-Q: Aquestive Therapeutics Reports Q3 Loss, Anaphylm Advances Amid Libervant Setback

Aquestive Therapeutics reported a significant increase in net loss and revenue decline for Q3 2025, while its lead product candidate Anaphylm progresses towards a January 2026 FDA decision, and Libervant's U.S. market access was vacated by a court ruling.

Summary

• Net loss for the three months ended September 30, 2025, increased to $15,446,000 from $11,509,000 in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $51,924,000 from $27,082,000 in the prior year period.
• Total revenues decreased by 5% to $12,807,000 for the three months ended September 30, 2025, compared to $13,542,000 in the prior year.
• Total revenues decreased by 31% to $31,530,000 for the nine months ended September 30, 2025, compared to $45,694,000 in the prior year.
• Cash and cash equivalents increased to $129,063,000 as of September 30, 2025, from $71,546,000 at December 31, 2024, primarily due to financing activities.
• Anaphylm's New Drug Application (NDA) was accepted by the FDA on June 16, 2025, with a PDUFA target action date of January 31, 2026.
• The FDA informed the company on September 4, 2025, that an advisory committee meeting would not be required for Anaphylm.
• Libervant's U.S. market access for ARS patients aged two to five years was vacated by a U.S. District Court ruling on February 14, 2025, due to Orphan Drug Exclusivity (ODE) concerns, leading to the cessation of marketing activities.
• The company entered into a purchase and sale agreement with RTW Investments LP on August 13, 2025, for $75,000, contingent on Anaphylm's FDA approval by a specified date and refinancing of existing debt, involving tiered revenue share payments.
• An underwritten public offering on August 14, 2025, raised net proceeds of $79,900,000.
• The Haisco Agreement and MTPA License Agreement for Exservan were terminated in June 2024, impacting license and royalty revenue recognition in the prior year.
• Suboxone branded products retain approximately 25% film market share due to generic competition.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company secured significant financing and Anaphylm is progressing well towards a PDUFA date without an advisory committee, the substantial increase in net loss, revenue decline, increased operating cash burn, and the major setback for Libervant's market access create significant headwinds and uncertainty. The legal risks are also notable.

Positives

• Cash and cash equivalents significantly increased to $129,063,000 as of September 30, 2025, providing near-term liquidity.
• Anaphylm's NDA was accepted by the FDA with a PDUFA target action date of January 31, 2026, indicating progress towards potential approval.
• The FDA confirmed that an advisory committee meeting would not be required for Anaphylm, potentially streamlining the approval process.
• Positive topline data from multiple Anaphylm clinical studies (pivotal, temperature/pH, self-administration PK, OASIS) consistently demonstrated favorable PK/PD profiles and safety.
• Two additional U.S. patents related to Anaphylm were issued on October 8, 2025, extending patent protection into 2037.
• A $500,000 milestone payment was earned in Q2 2025 from Zambon in connection with the sale of Emylif.
• The purchase and sale agreement with RTW Investments LP for $75,000 provides a significant funding opportunity contingent on Anaphylm's approval and debt refinancing.

Negatives

• Net loss significantly increased to $15,446,000 for the three months and $51,924,000 for the nine months ended September 30, 2025, compared to prior year periods.
• Total revenues decreased by 5% for the three months and 31% for the nine months ended September 30, 2025, primarily due to lower license and royalty revenue and decreased Suboxone sales.
• Libervant's U.S. market access for ARS patients aged two to five years was vacated by a U.S. District Court ruling, leading to the cessation of marketing activities and conversion to 'tentative approval'.
• The company likely will not receive additional contingent payments of up to $75,000,000 under the KYNMOBI Monetization Agreement due to Sunovion's voluntary withdrawal of the product from U.S. and Canadian markets.
• Net cash used for operating activities increased to $43,963,000 for the nine months ended September 30, 2025, from $29,270,000 in the prior year, indicating higher cash burn.
• Suboxone branded products' market share has eroded to approximately 25% due to generic competition, impacting manufacturing revenue.
• Termination of Haisco and MTPA agreements for Exservan resulted in a loss of future contingent payments and manufacturing revenue from those partnerships.

Risks

• Government shutdowns could significantly delay or disrupt the FDA's review and approval processes for product candidates like Anaphylm, potentially delaying receipt of the $75,000,000 payment from RTW Investments LP.
• The FDA may require additional clinical studies for Anaphylm approval, increasing costs and delays.
• The company's ability to generate sufficient clinical data for approval of product candidates, including PK/PD comparability for Anaphylm, is a risk.
• Competition from existing products, including generics, and new competing products (e.g., nasal spray for anaphylaxis) could impact market acceptance and sales.
• Commercializing new products involves technology, financial, market, implementation risks, and regulatory limitations.
• Developing a sales and marketing capability for Anaphylm, Libervant, and AQST-108, if approved, requires significant investment and carries execution risk.
• The company's ability to raise sufficient capital and cash resources, including through its ATM facility and revenues from operations, to fund operating needs, debt principal payments, and future development is uncertain.
• Obligations under the Purchase Agreement and Royalty Rights Agreement require payment of a portion of revenues, impacting funding for operations and debt payments.
• Manufacturing capabilities may be insufficient to support demand for product candidates if approved.
• Eroding market share for Suboxone, a sunsetting product, accounts for a substantial part of current operating revenue.
• Risk of default on debt instruments, particularly the 13.5% Senior Secured Notes with principal payments starting in June 2026.
• Intellectual property rights and infringement claims, including the timely issuance of patents for Anaphylm and AQST-108, pose risks.
• Legal proceedings, including the California Litigation, Neurelis FDA Lawsuit (Libervant), and Suboxone Product Liability Litigation, could result in significant losses or impact market access.
• Regulatory changes, including those affecting product pricing, reimbursement, or access, could adversely affect the business.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances product candidates through development and clinical trials, seeking regulatory approval and commercialization for Anaphylm. A product launch for Anaphylm is planned for Q1 2026, if approved by the FDA. The company plans to initiate a Phase 2a clinical trial for AQST-108 in the first half of 2026. The company will need to raise significant funding to support the continued commercialization of Anaphylm over the long-term and expects to be dependent on external financing until profitability is achieved.

Management Comments

• Management expects the company to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials, ultimately seeking regulatory approval and commencing commercialization activities for Anaphylm, if approved by the FDA.
• Management believes the company's on-going business, existing cash and cash equivalents, expense management activities, as well as access to the equity capital markets through its ATM facility, provide near term liquidity for the company to fund its operating needs for at least the next twelve months.
• Management believes the Adrenaverse platform has demonstrated the ability to harness the therapeutic potential of epinephrine through highly differentiated prodrug formulations, which can achieve absorption, provide sustained local exposure and avoid systemic exposure.
• Management believes the application of proprietary PharmFilm technology is particularly valuable and relevant to patients suffering from certain CNS disorders to meet patients unmet medical needs and to solve patients therapeutic problems.

Industry Context

The pharmaceutical industry is highly competitive and regulated. Aquestive Therapeutics operates in the specialized areas of severe allergic reactions (anaphylaxis) and CNS disorders (epilepsy). The market for epinephrine auto-injectors is dominated by established players like EpiPen and Auvi-Q, with a recent nasal spray device also approved. Anaphylm aims to disrupt this market with a non-device, orally delivered epinephrine. The epilepsy market for rescue therapies also has established rectal gel and nasal spray options, which Libervant aimed to challenge with an oral film. The company's reliance on its PharmFilm technology for drug delivery positions it within the specialty pharma segment focused on improved patient administration and compliance. The ongoing legal challenges and market share erosion for Suboxone highlight the intense generic competition and patent expiry risks common in the industry.

Comparison to Industry Standards

• Anaphylm's clinical results showing PK/PD biocomparability to auto-injectors like EpiPen and Auvi-Q suggest it could meet efficacy standards for emergency treatment of anaphylaxis, potentially offering a differentiated oral administration route.
• Libervant's initial FDA approval for ARS patients aged 2-5 years positioned it as the first and only orally administered rescue product for this population, offering a potential advantage over existing diazepam rectal gel and nasal spray products (e.g., Neurelis' Valtoco). However, the court's vacating of this approval due to ODE concerns highlights the significant regulatory hurdles and competitive landscape in orphan drug markets, where exclusivity can be a major barrier.
• Suboxone's market share erosion to approximately 25% for branded film products is typical for drugs facing generic competition after patent expiry, reflecting a common industry trend where branded products lose significant market share to lower-cost alternatives.

Management Changes

Legal Proceedings

• California Litigation (Neurelis, Inc. v. Aquestive Therapeutics, Inc.): Neurelis filed a lawsuit alleging Unfair Competition, Defamation, and Malicious Prosecution. The court struck portions of the claims, and a Third Amended Complaint was filed. Trial is scheduled for January 5, 2026. The ultimate outcome or loss cannot be determined or reasonably estimated.
• Neurelis FDA Lawsuit (Neurelis v. Califf, et al.): Neurelis challenged the FDA's approval of Libervant for ARS patients aged two to five years. The U.S. District Court ruled in favor of Neurelis on February 14, 2025, vacating Libervant's approval. The FDA filed an appeal, and the company withdrew its appeal. The ultimate outcome or loss, or whether FDA will grant U.S. market access, cannot be determined or reasonably estimated.
• Suboxone Product Liability Litigation: The company is a defendant in a Multidistrict Litigation (MDL) in Ohio and proposed class action lawsuits in Canada, alleging dental injuries from Suboxone Sublingual Film. Indivior has agreed to defend the company in the U.S. MDL. The company's motion to dismiss the MDL was granted for all claims except design defect claims. The ultimate outcome or loss cannot be determined or reasonably estimated.

Stakeholder Impact

• Shareholders: Experience significant dilution from recent equity offerings. The increased net loss and revenue decline negatively impact profitability. Anaphylm's potential approval and associated revenue share agreement could provide future value, but Libervant's market access setback creates uncertainty. Legal proceedings pose ongoing financial and reputational risks.
• Employees: Severance expenses contributed to increased R&D and G&A personnel costs. Share-based compensation is a significant component of overall compensation. Management's 10b5-1 plans indicate planned stock sales.
• Customers (Licensees): Indivior and Hypera remain major customers, accounting for 72% and 18% of total revenue, respectively, for the nine months ended September 30, 2025. Termination of agreements with Haisco and MTPA impacts their product portfolios. The vacating of Libervant's approval affects patients and prescribers who might have used the product.
• Creditors: The company has substantial debt, including $45,000,000 in 13.5% Senior Secured Notes with principal payments starting in June 2026. The Royalty Right Agreements also represent a debt-like obligation. The recent capital raise improves liquidity to meet near-term obligations, but long-term profitability is crucial for debt servicing.

Next Steps

• FDA decision on Anaphylm's NDA by the PDUFA target action date of January 31, 2026.
• Initiate product launch of Anaphylm in Q1 2026, if approved by the FDA.
• Continue pre-clinical development studies for AQST-108.
• Open an IND for AQST-108 in Q4 2025.
• Initiate Phase 2a clinical trial for AQST-108 in H1 2026.
• Monitor the FDA's appeal of the District Court's ruling regarding Libervant's market access.
• Await FDA response on the request for Libervant approval based on clinical superiority.
• File for FDA approval for use of Libervant for ARS patients aged between 6 and 11 years prior to the expiration of Valtoco's ODE.
• Continue to pursue regulatory strategies for Anaphylm outside the United States, including planned submission for a Marketing Authorization in Canada and a Marketing Authorization Application to the EMA.
• Manage business costs to reflect anticipated general decline in Suboxone revenue and other external factors.
• Commence principal payments on 13.5% Senior Secured Notes starting June 30, 2026.
• Trial for California Litigation (Neurelis v. Aquestive) scheduled for January 5, 2026.
• Monitor progress of Suboxone product liability litigation in the U.S. and Canada.

Key Dates

Recommendation

The company faces a mixed bag of significant challenges and promising developments. The substantial increase in net losses and revenue decline, coupled with increased operating cash burn, paints a negative financial picture. The vacating of Libervant's FDA approval is a major setback, creating uncertainty around a previously approved product. However, the company has significantly bolstered its cash position through recent capital raises, providing a longer runway. The Anaphylm program shows strong clinical progress, an accepted NDA, a PDUFA date, and no advisory committee, which are significant positives that could drive future value. The extended patent protection for Anaphylm further strengthens its potential. Given the high-risk, high-reward nature of pharmaceutical development, the current situation warrants a 'hold' recommendation. Investors should closely monitor the Anaphylm FDA decision, the outcome of the Libervant legal proceedings, and the company's ability to manage its debt obligations and achieve profitability.

Keywords

Aquestive Therapeutics, AQST, Anaphylm, epinephrine, sublingual film, anaphylaxis, FDA approval, PDUFA, Libervant, diazepam buccal film, seizure clusters, Orphan Drug Exclusivity, SEC filing, 10-Q, pharmaceuticals, drug development, clinical trials, biotechnology, revenue share, capital raise, net loss, cash flow, patent protection, legal proceedings, Suboxone, Adrenaverse, AQST-108, PharmFilm